Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 1, 2007, Pages 39-45

  Cai, C ^a   Omwancha, J ^a   Hsieh, C L ^a   Shemshedini, L ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ETOPOSIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 4;

ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; METASTASIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROTESTOSTERONE; DRUG RESISTANCE, NEOPLASM; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METHOTREXATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 33847642501     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500912     Document Type: Article

References (25)

1. Marquardt D, McCrone S, Center MS. Mechanisms of drug resistance in HL60 cells: Detection of resistance associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of p-glycoprotein. Cancer Res 1990; 50: 1426-1430.
2. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al. Overexpression of a transporter gene in multidrug-resistance human lung cancer cell line. Science 1992; 258: 1650-1654.
3. Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta 1999; 1461: 347-357.
4. Thomas E. The human ATP-binding cassette transporter genes: From the bench to the bedside. Curr Mol Medic 2001; 1: 45-65.
5. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-1302.
6. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 275: 30069-30074.
7. Wijnholds J, Mol CA, Deemter L, De Haas M, Scheffer GL, Baas F et al. Multispecific resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000; 97: 7476-7481.
8. Lee K, Klein-Szanto AJP, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 2000; 92: 1934-1940.
9. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chern 2003; 278: 17664-17671.
10. Glen R, Peter W, Noam Z, Mercel DH, Liesbeth VD, Jan W et al. characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003; 63: 1094-1103.
11. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 2003; 253: 89-101.
12. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999; 26: 407-421.
13. Gleave ME, Hsieh JT, Gao C, Von Eschenbach A, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992; 52: 1598-1605.
14. Chen S-Y, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh C-L et al. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene 2006; May 29 [Epub ahead of print].
15. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997; 126: 59-73.
16. Yuan S, Trachtenberg J, Mills; GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 53: 1304-1311.
17. Bubulya A, Chen SY, Fisher CJ, Zheng Z, Shen XQ, Shemshedini L. c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor. J Biol Chem 2001; 276: 44704-44711.
18. Igawa T, Lin F, Lee M, Karan D, Batra KS, Lin M. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002; 50: 222-235.
19. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein E ZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
20. Koksal IT, Ozcan F, Kilicaslan I, Tefekli A. Expression of E-cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: correlation with pathological features. Pathology 2002; 34: 233-238.
21. Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 2002; 4: 1-9.
22. Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G et al. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 2006; 66: 2673-2682.
23. Koike K, Kwabe T, Tanaka T, Toh S, Uchiumi T, Wada M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57: 5475-5479.
24. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999; 96: 6914-6919.
25. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G et al. MRP4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004; 17: 7612-7621.